Niaoduqing Granules in Older Adults With Impaired Kidney Function

NCT07741292 · tracked via the Priya Life Science China tracker

Sponsor

Huashan Hospital

Phase

Phase 4

Started

2025-12-01

Last updated

2026-08-03

Condition(s) studied

Chronic Kidney Disease

Investigational drug(s) / intervention(s)

Intervention Name

Intervention Name: Niaoduqing Granules will be administered orally at a dose of 5 g three times daily at 6:00, 12:00, and 18:00 after meals with warm water for 12 months. Usual treatments for chronic kidney disease, age-related comorbidities, and other chronic conditions may be continued or adjusted according to specialist recommendations.

Study summary

This prospective real-world study will evaluate the clinical benefits of Niaoduqing Granules in older adults with impaired kidney function. Approximately 300 participants aged over 60 years with stage 3 to 5 chronic kidney disease who are not receiving dialysis will be enrolled at Huashan Hospital, Fudan University. The study will examine whether treatment with Niaoduqing Granules is associated with slower kidney function decline and improvements in nutrition, frailty, and other health outcomes.

Participants will receive 5 g of Niaoduqing Granules three times daily after meals for 12 months, while continuing their usual treatment for chronic diseases as directed by their physicians. Kidney function, laboratory results, nutritional status, frailty, cardiovascular and cerebrovascular events, and survival will be assessed during follow-up. Blood, urine, and stool samples will also be collected to study changes in gut microorganisms and blood metabolites that may help explain how Niaoduqing Granules affect health. Participants will be followed for up to 60 months.

Eligibility

Sex

ALL

Min age

61 Years

Max age

—

Healthy volunteers

Inclusion Criteria: 1. Participants with stage 3 to 5 chronic kidney disease who are not receiving dialysis. 2. Age older than 60 years. 3. The participant or a family member has sufficient literacy and is able to comply with dietary diary recording and other study-related examinations. 4. The underlying cause of chronic kidney disease is clinically stable. Exclusion Criteria: 1. Malignancy, severe cardiovascular disease, osteoporosis, or severe hematopoietic system disease. 2. Active infection, defined as C-reactive protein greater than 10 mg/L, or current use of nephrotoxic medications. 3. Limb paralysis or major limb impairment. 4. Use of immunosuppressive therapy, including cyclosporine or tacrolimus, within the 3 months before cohort enrollment, or use of corticosteroids at a dose equivalent to more than 10 mg/day of prednisone. 5. Severe gastrointestinal disease affecting nutrient absorption. 6. Current participation in, or participation within the previous month in, another study related to diet or medication. 7. Known allergy to Niaoduqing Granules. 8. Any condition that, in the investigator's judgment, makes the participant unsuitable for the study.

Primary outcome measure(s)

Occurrence of Rapid Kidney Function Decline — Every 12 months from baseline through Month 60
Rapid kidney function decline is defined as an annual decrease in estimated glomerular filtration rate (eGFR) of more than 5%. The occurrence of rapid kidney function decline will be determined using serial kidney function measurements obtained during follow-up.

Trial sites (1)

Facility	City	Region	Status
Huashan Hospital, Fudan University	Shanghai	Shanghai Municipality	Recruiting

More Huashan Hospital trials in China

Real-World Study of Enarodustat for Anemia in Non-Dialysis CKD Patients Recruiting

Bilateral Single-Electrode VO Combined With STN-DBS for Treating Meige Syndrome Recruiting

The Impact of Probiotic Intervention on the Gut Microbiota and Bowel Function Recruiting

The Role of B7-H4 in Tumor Vaccine Recruiting

Precision Diagnosis and Prospective Cohort Study for Myasthenia Gravis: Multicenter Analysis in China Recruiting

Other trials for the same condition

A Study of the Effect and Safety of HS-10390 in the Treatment of Participants With Chronic Kidney Disease Starting soon

Assessment and Management of Multiple Drug Use in Elderly Chronic Disease Patients Recruiting

Multimodal Imaging Assessment of Chronic Kidney Disease Patients at Different Stages From a Cardio-Renal Interaction Perspective Recruiting

A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care Setting Active, not recruiting

Renal Efficacy and Safety of the Novel Oral Small-Molecule GLP-1RA HRS-7535 Evaluated in Participants With Chronic Kidney Disease Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07741292 on ClinicalTrials.gov ↗ ← All trials in China